All IndicationsOncologyPhase 3Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 1
🎗️
Prostate Cancer
8
Companies
9
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Competitors
CADL
Candel Therapeutics, Inc.
Aglatimagene besadenovec + valacyclovir
CADL
Candel Therapeutics, Inc.
aglatimagene besadenovec
CASI
CASI Pharmaceuticals, Inc.
Panzem® NCD
LLY
Eli Lilly and Company
prednisone
SNY
Sanofi
Cabazitaxel XRP6258
4503.T
Astellas Pharma Inc.
CP-461
BTAI
BioXcel Therapeutics, Inc.
BXCL701 plus Pembrolizumab
BGMS
Bio Green Med Solution, Inc.
PRX302
AMGN
Amgen Inc.
AMG 509
Fast Track
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| CADL Candel Therapeutics, Inc. | Aglatimagene besadenovec + valacyclovir | Phase 3 | — | — | — |
| CADL Candel Therapeutics, Inc. | aglatimagene besadenovec | Phase 2 | — | — | — |
| CASI CASI Pharmaceuticals, Inc. | Panzem® NCD | Phase 2 | — | — | — |
| LLY Eli Lilly and Company | prednisone | Phase 2 | — | — | — |
| SNY Sanofi | Cabazitaxel XRP6258 | Phase 2 | — | — | — |
| 4503.T Astellas Pharma Inc. | CP-461 | Phase 2 | — | — | — |
| BTAI BioXcel Therapeutics, Inc. | BXCL701 plus Pembrolizumab | Phase 2 | — | — | — |
| BGMS Bio Green Med Solution, Inc. | PRX302 | Phase 2 | — | — | — |
| AMGN Amgen Inc. | AMG 509 | Phase 1 | FT | — | — |
Development Stage Distribution
Phase 3
1
Phase 2
7
Phase 1
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.